Northern Trust
TXG icon

Northern Trust’s 10x Genomics TXG Stock Holding History

Northern Trust’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.2M Buy
1,048,005
+54,625
+5% +$1.09M ﹤0.01% 1610
2025
Q4 		$16.2M Sell
993,380
-45,883
-4% -$693K ﹤0.01% 1807
2025
Q3 		$12.1M Buy
1,039,263
+29,951
+3% +$391K ﹤0.01% 2004
2025
Q2 		$11.7M Buy
1,009,312
+460,280
+84% +$4.2M ﹤0.01% 1972
2025
Q1 		$4.79M Sell
549,032
-12,634
-2% -$159K ﹤0.01% 2425
2024
Q4 		$8.07M Sell
561,666
-31,923
-5% -$504K ﹤0.01% 2245
2024
Q3 		$13.4M Sell
593,589
-55,221
-9% -$1.14M ﹤0.01% 1889
2024
Q2 		$12.6M Buy
648,810
+56,948
+10% +$1.49M ﹤0.01% 1855
2024
Q1 		$22.2M Buy
591,862
+122,227
+26% +$5.37M ﹤0.01% 1518
2023
Q4 		$26.3M Sell
469,635
-2,450
-0.5% -$107K ﹤0.01% 1423
2023
Q3 		$19.5M Buy
472,085
+11,599
+3% +$603K ﹤0.01% 1561
2023
Q2 		$25.7M Buy
460,486
+3,835
+0.8% +$208K ﹤0.01% 1421
2023
Q1 		$25.5M Buy
456,651
+58,937
+15% +$2.75M 0.01% 1395
2022
Q4 		$14.5M Buy
397,714
+4,779
+1% +$156K ﹤0.01% 1760
2022
Q3 		$11.2M Buy
392,935
+6,341
+2% +$242K ﹤0.01% 1897
2022
Q2 		$17.5M Sell
386,594
-88,125
-19% -$4.57M ﹤0.01% 1623
2022
Q1 		$36.1M Buy
474,719
+5,285
+1% +$462K 0.01% 1265
2021
Q4 		$69.9M Sell
469,434
-50,359
-10% -$7.71M 0.01% 868
2021
Q3 		$75.7M Buy
519,793
+42,144
+9% +$7.24M 0.01% 806
2021
Q2 		$93.5M Buy
477,649
+68,786
+17% +$12.4M 0.02% 707
2021
Q1 		$74M Buy
408,863
+13,132
+3% +$2.27M 0.01% 834
2020
Q4 		$56M Buy
395,731
+107,242
+37% +$15.6M 0.01% 984
2020
Q3 		$36M Buy
288,489
+105,361
+58% +$11.1M 0.01% 1145
2020
Q2 		$16.4M Buy
183,128
+158,666
+649% +$12.4M ﹤0.01% 1777
2020
Q1 		$1.52M Buy
24,462
+1,777
+8% +$139K ﹤0.01% 3004
2019
Q4 		$1.73M Buy
22,685
+14,471
+176% +$870K ﹤0.01% 3205
2019
Q3 		$414K Buy
+8,214
New +$455K ﹤0.01% 3587

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust's TXG Position: Q1 2026 in Review

Northern Trust increased its 10x Genomics (TXG) stake by 5.5% in Q1 2026, buying an estimated $1.09M and bringing the position to 1,048,005 shares worth $22.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1610.

Northern Trust first reported a position in TXG in Q3 2019 and has held it in 27 quarters since. The position peaked at $93.5M in Q2 2021. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Northern Trust held 1,048,005 shares of 10x Genomics worth $22.2M as of Q1 2026.
  • Northern Trust bought 54,625 10x Genomics shares in Q1 2026, an estimated $1.09M.
  • 10x Genomics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1610 holding.
  • Northern Trust first reported a position in 10x Genomics in Q3 2019 and has held it in 27 quarters since.
  • Northern Trust's 10x Genomics position peaked at $93.5M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.